We next assessed if acquired venetoclax resistance was associated with altered levels of BCL2 family members, as we detected in the intrinsically venetoclax-resistant lines and as previously suggested in venetoclax-treated CLL patients and in pre-clinical models of AML and other hematologic malignancies [35,37,42,43]. This evidence concerns the gene BCL2 and hematologic disorder.